This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected] Learn more

pDONR223-AXL Citations (4)

Plasmid Article: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Nov 24. ():.
PubMed Journal

Articles Citing pDONR223-AXL

Articles
AXL mediates resistance to cetuximab therapy. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, Wheeler DL. Cancer Res. 2014 Sep 15;74(18):5152-64. doi: 10.1158/0008-5472.CAN-14-0294. Epub 2014 Aug 18. PubMed
Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells. Vouri M, Croucher DR, Kennedy SP, An Q, Pilkington GJ, Hafizi S. Oncogenesis. 2016 Oct 24;5(10):e266. doi: 10.1038/oncsis.2016.66. PubMed
Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression. von Massenhausen A, Bragelmann J, Billig H, Thewes B, Queisser A, Vogel W, Kristiansen G, Schrock A, Bootz F, Brossart P, Kirfel J, Perner S. Int J Mol Sci. 2016 Dec 22;18(1). pii: E7. doi: 10.3390/ijms18010007. PubMed
Oncogenic Kinase-Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stem-like Cells. Zhou Z, Li M, Zhang L, Zhao H, Sahin O, Chen J, Zhao JJ, Songyang Z, Yu D. Cancer Res. 2018 May 1;78(9):2248-2261. doi: 10.1158/0008-5472.CAN-17-2726. Epub 2018 Feb 12. PubMed

If you have published an article using this plasmid, please email us at [email protected] to have your article added to this page.